Fig. 2From: Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysisResponder rates. Proportion of patients with responder rates of 25%, 50%, 75%, and 100% based on monthly migraine days. EM, episodic migraine; CM, chronic migraine; ALL, all patients; RR, responder rateBack to article page